{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T18:46:09Z","timestamp":1781289969351,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Development Center Americas, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Maribavir is approved for management of post-transplant cytomegalovirus (CMV) infections refractory and\/or resistant to CMV therapies at a dose of 400\u00a0mg twice daily (BID). Population pharmacokinetic (PopPK) and exposure\u2013response analyses were conducted to support the appropriateness of 400\u00a0mg BID dosing. A PopPK model was developed using non-linear mixed-effects modeling with pooled maribavir plasma concentration\u2013time data from phase 1 and 2 studies (from 100\u00a0mg up to 1200\u00a0mg as single or repeated doses) and the phase 3 SOLSTICE study (400\u00a0mg BID). Exposure\u2013response analyses were performed for efficacy, safety, and viral resistance based on data collected in the SOLSTICE study. Maribavir PK after oral administration was adequately described by a two-compartment model with first-order elimination, first-order absorption, and an absorption lag-time. There was no evidence that maribavir PK was affected by age, sex, race, diarrhea, vomiting, disease characteristics, or concomitant use of histamine H<jats:sub>2<\/jats:sub> blockers, or proton pump inhibitors. In the SOLSTICE study, higher maribavir exposure was not associated with increased probability of achieving CMV DNA viremia clearance, nor with reduced probability of treatment-emergent maribavir-resistant CMV mutations. A statistically significant association with maribavir exposure was identified for taste disturbance, fatigue, and treatment-emergent serious adverse events, while transplant type, enrollment region, CMV DNA level at baseline, and\/or CMV resistance at baseline were identified as additional risk factors for these safety outcomes. In conclusion, the findings of these PopPK and exposure\u2013response analyses provide further support for the recommended maribavir dose of 400\u00a0mg BID.<\/jats:p>","DOI":"10.1007\/s10928-024-09939-2","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T20:24:50Z","timestamp":1727468690000},"page":"887-904","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Population pharmacokinetics and exposure\u2013response relationships of maribavir in transplant recipients with cytomegalovirus infection"],"prefix":"10.1007","volume":"51","author":[{"given":"Ivy H.","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Jomphe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie H.","family":"Gosselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"9939_CR1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","volume":"19","author":"P Griffiths","year":"2021","unstructured":"Griffiths P, Reeves M (2021) Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol 19:759\u2013773. https:\/\/doi.org\/10.1038\/s41579-021-00582-z","journal-title":"Nat Rev Microbiol"},{"key":"9939_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/microorganisms8040515","volume":"8","author":"M Steingruber","year":"2020","unstructured":"Steingruber M, Marschall M (2020) The cytomegalovirus protein kinase pUL97: host interactions, regulatory mechanisms and antiviral drug targeting. Microorganisms 8:515. https:\/\/doi.org\/10.3390\/microorganisms8040515","journal-title":"Microorganisms"},{"key":"9939_CR3","doi-asserted-by":"publisher","first-page":"e12852","DOI":"10.1111\/tid.12852","volume":"20","author":"B Pierce","year":"2018","unstructured":"Pierce B, Richardson CL, Lacloche L, Allen A, Ison MG (2018) Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: a single-center study. Transpl Infect Dis 20:e12852. https:\/\/doi.org\/10.1111\/tid.12852","journal-title":"Transpl Infect Dis"},{"key":"9939_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/QCO.0000000000000170","volume":"28","author":"S Chou","year":"2015","unstructured":"Chou S (2015) Approach to drug-resistant cytomegalovirus in transplant recipients. Curr Opin Infect Dis 28:293\u2013299. https:\/\/doi.org\/10.1097\/QCO.0000000000000170","journal-title":"Curr Opin Infect Dis"},{"key":"9939_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S2055-6640(20)30457-X","volume":"2","author":"M McIntosh","year":"2016","unstructured":"McIntosh M, Hauschild B, Miller V (2016) Human cytomegalovirus and transplantation: drug development and regulatory issues. J Virus Erad 2:143\u2013148","journal-title":"J Virus Erad"},{"key":"9939_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1128\/AAC.00561-13","volume":"58","author":"LR Minces","year":"2014","unstructured":"Minces LR, Nguyen MH, Mitsani D, Shields RK, Kwak EJ, Silveira FP, Abdel-Massih R, Pilewski JM, Crespo MM, Bermudez C, Bhama JK, Toyoda Y, Clancy CJ (2014) Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother 58:128\u2013135. https:\/\/doi.org\/10.1128\/AAC.00561-13","journal-title":"Antimicrob Agents Chemother"},{"key":"9939_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1600-6143.2011.03766.x","volume":"12","author":"L Couzi","year":"2012","unstructured":"Couzi L, Helou S, Bachelet T, Moreau K, Martin S, Morel D, Lafon ME, Boyer B, Alain S, Garrigue I, Merville P (2012) High incidence of Anticytomegalovirus drug resistance among D\u2009+\u2009R\u2009\u2013\u2009kidney transplant recipients receiving preemptive therapy. Am J Transpl 12:202\u2013209. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03766.x","journal-title":"Am J Transpl"},{"key":"9939_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/rmv.615","volume":"19","author":"MN Prichard","year":"2009","unstructured":"Prichard MN (2009) Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol 19:215\u2013229. https:\/\/doi.org\/10.1002\/rmv.615","journal-title":"Rev Med Virol"},{"key":"9939_CR9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cid\/ciab988","volume":"75","author":"RK Avery","year":"2022","unstructured":"Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, Duarte RF, Florescu DF, Kamar N, Kumar D, Maertens J, Marty FM, Papanicolaou GA, Silveira FP, Witzke O, Wu J, Sundberg AK, Fournier M, SOLSTICE Trial Investigators (2022) Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis 75:690\u2013701. https:\/\/doi.org\/10.1093\/cid\/ciab988","journal-title":"Clin Infect Dis"},{"key":"9939_CR10","unstructured":"Takeda Pharmaceuticals America Inc (2023) LIVTENCITY (maribavir) US prescribing information. https:\/\/content.takeda.com\/?contenttype=pi&product=liv&language=eng&country=usa&documentnumber=1. Accessed 19 October 2023"},{"key":"9939_CR11","unstructured":"Takeda Pharmaceuticals International AG Ireland Branch (2023) LIVTENCITY summary of product characteristics (EMA). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/livtencity-epar-product-information_en.pdf. Accessed 19 October 2023"},{"key":"9939_CR12","doi-asserted-by":"publisher","unstructured":"Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA 3rd, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE, Stanat SC, Drach JC, Townsend LB, Koszalka GW (2002) Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 46:2365\u20132372. https:\/\/doi.org\/10.1128\/AAC.46.8.2365-2372.2002","DOI":"10.1128\/AAC.46.8.2365-2372.2002"},{"key":"9939_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad709","author":"GA Papanicolaou","year":"2023","unstructured":"Papanicolaou GA, Avery RK, Cordonnier C, Duarte RF, Haider S, Maertens J, Peggs KS, Solano C, Young JH, Fournier M, Murray RA, Wu J, Winston DJ, AURORA Trial Investigators (2023) Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciad709","journal-title":"Clin Infect Dis"},{"key":"9939_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/rmv.574","volume":"18","author":"S Chou","year":"2008","unstructured":"Chou S (2008) Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 18:233\u2013246. https:\/\/doi.org\/10.1002\/rmv.574","journal-title":"Rev Med Virol"},{"key":"9939_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/infdis\/jiad293","volume":"229","author":"S Chou","year":"2024","unstructured":"Chou S, Alain S, Cervera C, Chemaly RF, Kotton CN, Lundgren J, Papanicolaou GA, Pereira MR, Wu JJ, Murray RA, Buss NE, Fournier M (2024) Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients. J Infect Dis 229:413\u2013421. https:\/\/doi.org\/10.1093\/infdis\/jiad293","journal-title":"J Infect Dis"},{"key":"9939_CR16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/infdis\/jiaa462","volume":"226","author":"S Chou","year":"2022","unstructured":"Chou S, Song K, Wu J, Bo T, Crumpacker C (2022) Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection. J Infect Dis 226:576\u2013584. https:\/\/doi.org\/10.1093\/infdis\/jiaa462","journal-title":"J Infect Dis"},{"key":"9939_CR17","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","volume":"381","author":"J Maertens","year":"2019","unstructured":"Maertens J, Cordonnier C, Jaksch P, Poir\u00e9 X, Uknis M, Wu J, Wijatyk A, Saliba F, Witzke O, Villano S (2019) Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med 381:1136\u20131147. https:\/\/doi.org\/10.1056\/NEJMoa1714656","journal-title":"N Engl J Med"},{"key":"9939_CR18","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/cid\/ciy706","volume":"68","author":"GA Papanicolaou","year":"2019","unstructured":"Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, Wijatyk A, Wu J, Boeckh M, Marty FM, Villano S (2019) Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infect Dis 68:1255\u20131264. https:\/\/doi.org\/10.1093\/cid\/ciy706","journal-title":"Clin Infect Dis"},{"key":"9939_CR19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1128\/AAC.47.4.1334-1342.2003","volume":"47","author":"LH Wang","year":"2003","unstructured":"Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB (2003) Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 47:1334\u20131342. https:\/\/doi.org\/10.1128\/AAC.47.4.1334-1342.2003","journal-title":"Antimicrob Agents Chemother"},{"key":"9939_CR20","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1128\/AAC.46.8.2373-2380.2002","volume":"46","author":"GW Koszalka","year":"2002","unstructured":"Koszalka GW, Johnson NW, Good SS, Boyd L, Chamberlain SC, Townsend LB, Drach JC, Biron KK (2002) Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 46:2373\u20132380. https:\/\/doi.org\/10.1128\/AAC.46.8.2373-2380.2002","journal-title":"Antimicrob Agents Chemother"},{"key":"9939_CR21","doi-asserted-by":"publisher","first-page":"S370","DOI":"10.1016\/j.bbmt.2018.12.600","volume":"25","author":"I Song","year":"2019","unstructured":"Song I, Sun K, Ilic K, Martin P (2019) Summary of maribavir (SHP620) drug\u2009\u2013\u2009drug interactions based on accumulated clinical and nonclinical data. Biol Blood Marrow Transpl 25:S370\u2013371 (Abstract #556)","journal-title":"Biol Blood Marrow Transpl"},{"key":"9939_CR22","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1128\/AAC.00951-07","volume":"52","author":"DR Goldwater","year":"2008","unstructured":"Goldwater DR, Dougherty C, Schumacher M, Villano SA (2008) Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults. Antimicrob Agents Chemother 52:1794\u20131798. https:\/\/doi.org\/10.1128\/AAC.00951-07","journal-title":"Antimicrob Agents Chemother"},{"key":"9939_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2385","author":"G Chen","year":"2023","unstructured":"Chen G, Sun K, Michon I, Barter Z, Neuhoff S, Ghosh L, Ilic K, Song IH (2023) Physiologically-based pharmacokinetic modeling for maribavir to inform dosing in drug\u2013drug interaction scenarios with CYP3A4 inducers and inhibitors. J Clin Pharmacol. https:\/\/doi.org\/10.1002\/jcph.2385","journal-title":"J Clin Pharmacol"},{"key":"9939_CR24","volume-title":"7.4.3 ed","author":"S Beal","year":"2018","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ (2018) NONMEM user\u2019s guides (1989\u20132018). 7.4.3 ed. ICON plc, Gathersberg, MD, USA"},{"key":"9939_CR25","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/psp4.12422","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ (2019) NONMEM tutorial part II: estimation methods and advanced examples. CPT Pharmacometrics Syst Pharmacol 8:538\u2013556. https:\/\/doi.org\/10.1002\/psp4.12422","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9939_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35:401\u2013421. https:\/\/doi.org\/10.1007\/s10928-008-9094-4","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9939_CR27","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.1047","volume":"21","author":"G Heinze","year":"2002","unstructured":"Heinze G, Schemper M (2002) A solution to the problem of separation in logistic regression. Stat Med 21:2409\u20132419. https:\/\/doi.org\/10.1002\/sim.1047","journal-title":"Stat Med"},{"key":"9939_CR28","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/cpt.2456","volume":"111","author":"M Prohn","year":"2022","unstructured":"Prohn M, Cho CR, Viberg A, Dykstra K, Davis C, Sabato P, Stone J, Badshah C, Murata Y, Leavitt R, Fancourt C, Macha S (2022) Exposure\u2009\u2013\u2009response analyses of letermovir following oral and intravenous administration in allogeneic hematopoietic cell transplantation recipients. Clin Pharmacol Ther 111:485\u2013495. https:\/\/doi.org\/10.1002\/cpt.2456","journal-title":"Clin Pharmacol Ther"},{"key":"9939_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/psp4.12943","volume":"12","author":"K Sun","year":"2023","unstructured":"Sun K, Hayes S, Farrell C, Song IH (2023) Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus. CPT Pharmacometrics Syst Pharmacol 12:719\u2013723. https:\/\/doi.org\/10.1002\/psp4.12943","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9939_CR30","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11:558\u2013569. https:\/\/doi.org\/10.1208\/s12248-009-9133-0","journal-title":"AAPS J"},{"key":"9939_CR31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/cpdd.1247","volume":"12","author":"I Song","year":"2023","unstructured":"Song I, Suttle B, Wu J, Ilic K (2023) Pharmacokinetics and safety evaluation of maribavir in healthy Japanese and matched white participants: a phase 1, open-label study. Clin Pharmacol Drug Dev 12:645\u2013654. https:\/\/doi.org\/10.1002\/cpdd.1247","journal-title":"Clin Pharmacol Drug Dev"},{"key":"9939_CR32","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jcph.2155","volume":"63","author":"I Song","year":"2023","unstructured":"Song I, Chen G, Wu J, Ilic K (2023) Maribavir pharmacokinetics and safety in participants with moderate hepatic impairment: a phase 1, open-label, single-dose, parallel group study. J Clin Pharmacol 63:250\u2013258. https:\/\/doi.org\/10.1002\/jcph.2155","journal-title":"J Clin Pharmacol"},{"key":"9939_CR33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/0091270006296765","volume":"47","author":"SK Swan","year":"2007","unstructured":"Swan SK, Smith WB, Marbury TC, Schumacher M, Dougherty C, Mico BA, Villano SA (2007) Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. J Clin Pharmacol 47:209\u2013217. https:\/\/doi.org\/10.1177\/0091270006296765","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09939-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-024-09939-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09939-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T12:06:05Z","timestamp":1732104365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-024-09939-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9939"],"URL":"https:\/\/doi.org\/10.1007\/s10928-024-09939-2","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IH Song, G Chen, and K Sun are employees of Takeda Development Center Americas, Inc., and receive stocks (and stock options) from Takeda. S Hayes and C Farrell are employees of ICON plc. C Jomphe and NH Gosselin are employees of Certara.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}